Northwest Biotherapeutics Inc completed its acquisition of Advent BioServices Ltd. on 2025-10-24, according to the Form 8-K Northwest Biotherapeutics Inc filed with the SEC on 2026-04-07. The filing states a price of $8.3 million.
| Acquirer | Northwest Biotherapeutics Inc |
|---|---|
| Acquired | Advent BioServices Ltd. |
| Completed | 2025-10-24 |
| Price stated in the filing | $8.3 million |
| Reported by | Northwest Biotherapeutics Inc (NWBO), the buyer |
| Filing | Form 8-K, filed 2026-04-07 |
Want the whole picture on Northwest Biotherapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Northwest Biotherapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Northwest Biotherapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
As previously announced, on October 24, 2025 (the "Closing Date"), Northwest Biotherapeutics, Inc. (the "Company") completed the acquisition of Advent BioServices Ltd. ("Advent"), a United Kingdom-based contract development and manufacturing organization (CDMO), from Toucan Holdings LLC (the "Seller"), pursuant to an acquisition agreement dated as of August 27, 2025.
The price, in the filing's words
The consideration for the acquisition consists of a purchase price of approximately $1.9 million ( 1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for manufacturing and related services already provided under services contracts prior to the acquisition, totaling approximately $8.3 million.
More from the filing
Prior to the acquisition, Advent provided the Company with product development, manufacturing, cryostorage and distribution services for the Company's DCVax product platform pursuant to various service agreements.
Following the acquisition, Advent became a wholly owned subsidiary of the Company.
The consideration for the acquisition is payable in installments over two years, beginning 3 months after the Closing Date, with potential acceleration after regulatory approval of the Company's DCVax -L product.
Quoted from Northwest Biotherapeutics Inc's Form 8-K.
This is the only completed acquisition Northwest Biotherapeutics Inc reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Northwest Biotherapeutics IncLook up Northwest Biotherapeutics Inc and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.